The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / When Will Generic Biologic Drugs Become Commercially Available?

When Will Generic Biologic Drugs Become Commercially Available?

August 1, 2013 • By Vibke Strand, MD, and Richard Brasington, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A Biologic by Any Other Name

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Biosimilar Drugs Face Challenges to Reach the U.S. Market
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
Explore This Issue
August 2013

The economic implications of biologic therapies are staggering. In 2009, 75% of small molecules (pills and capsules) dispensed were in generic form. By contrast, biologic medications account for 43% of the Medicare Part B budget! When will generic biologic disease-modifying antirheumatic drugs (DMARDs) become commercially available?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilar Basics

The term for a “generic biologic” is “biosimilar.” What is a biosimilar? It is a product that is highly similar to the “innovator” product, or brand-name biologic DMARD. Biologic DMARDs are different from small molecules in several important dimensions:

  • These are high-molecular-weight molecules with complicated, and unique, tertiary and quartenary structures. In other words, conformational changes in structure are important for function.
  • They are manufactured using recombinant DNA technology, which typically incorporates posttranslational modifications, especially glycosylation (if produced in mammalian cell lines).
  • Because they are protein molecules, they are immunogenic, to varying degrees.
  • Rather than being metabolized by the cytochrome P450 system, they are catabolized.
  • Given the parenteral administration required for protein molecules, the dose–response curves are nonlinear and sometimes less predictable than those seen with small molecules.

For these incredibly complex protein molecules, there are issues that do not apply to small molecule generics. For example, the manufacturing process for biologic DMARDs is much more complex than for small molecules, requiring large bioreactors and detailed, complicated biochemical processes. Purification of the final product is far more complex, and there are stability issues for these protein medications that do not apply to small molecules.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Biologics Go Global

Although patent expiration in the U.S. for several biologic therapies may be several years away (etanercept’s patent expires in 2026, infliximab’s and rituximab’s in 2018, adalimumab’s in 2017), biosimilars for these products are currently under development. In countries where the regulatory environments are much less stringent than in the U.S. or Europe, there already exist “bio-alike” products. In these countries (listed in Table 1), the cost of development has been significantly reduced, in part because randomized controlled trials to formally demonstrate equivalency have not been required.

Though these products have not undergone the stringent regulatory reviews required in the U.S., E.U., Canada, or Australia to demonstrate biosimilarity, economic pressures have propelled their development in those countries listed in Table 1.

Accordingly, in 2009 Congress passed legislation to address the process of bringing biosimilars to the U.S. market as part of healthcare reform. Termed the Biologics Price Competition and Innovative Act, this legislation defines the requirements for a biosimilar compared to the original “innovator” product as follows:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Must be “highly similar” to the original product;
  • Must involve the same mechanism of action;
  • Must have no clinically meaningful differences in potency, purity, or toxicity;
  • Must be expected to produce the same clinical results; and
  • Must utilize the same route of administration, dose, and strength.

A biosimilar may be determined to be sufficiently similar (i.e., “highly similar”) to the innovator product when it can be interchangeable with the original, such that no significant differences would be expected to occur if the patient were to be switched back and forth between the innovator drug and the biosimilar.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: available, Biologics, Biosimilars, Drugs, rheumatologyIssue: August 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
  • Biosimilar Drugs Face Challenges to Reach the U.S. Market
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)